CCS
IDXX icon

Crosspoint Capital Strategies’s Idexx Laboratories IDXX Stock Holding History

Crosspoint Capital Strategies’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,778
Closed -$132K – 1084
2015
Q3 		$132K Sell
1,778
-2,086
-54% -$149K 0.15% 140
2015
Q2 		$248K Buy
3,864
+2,802
+264% +$194K 0.07% 154
2015
Q1 		$82K Buy
1,062
+828
+354% +$64.4K 0.04% 223
2014
Q4 		$17K Buy
+234
New +$16.4K 0.01% 458

Other funds holding IDXX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Crosspoint Capital Strategies's IDXX Position: Q4 2015 in Review

Crosspoint Capital Strategies sold out of Idexx Laboratories (IDXX) in Q4 2015, closing a stake of 1,778 shares — an estimated $132K sold.

Crosspoint Capital Strategies first reported a position in IDXX in Q4 2014 and held it in 4 quarters. The position peaked at $248K in Q2 2015. 350 funds tracked by Wall St. Rank hold IDXX as of Q4 2015.

  • Crosspoint Capital Strategies reported no remaining Idexx Laboratories position as of Q4 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,778 Idexx Laboratories shares in Q4 2015, an estimated $132K.
  • Crosspoint Capital Strategies first reported a position in Idexx Laboratories in Q4 2014 and held it in 4 quarters.
  • Crosspoint Capital Strategies's Idexx Laboratories position peaked at $248K in Q2 2015.
  • 350 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2015, filed 16 Feb 2016.